摘要
目的比较表皮生长因子受体酪氨酸激酶抑制剂盐酸埃克替尼片和化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取2012年5月至2013年5月河北燕达医院收治的177例经病理学确诊的晚期NSCLC患者,按照治疗方法不同分为靶向组和化疗组,其中靶向组(88例)行盐酸埃克替尼片治疗,化疗组(89例)行培美曲塞联合顺铂治疗。比较两组患者5年生存率、无进展生存期、总生存期、疾病控制率、总缓解率和不良反应发生情况。结果随访至2018年7月30日,失访36例(靶向组17例,化疗组19例),失访率为20.34%;靶向组的无进展生存期为24.7个月,明显长于化疗组15.4个月(P<0.05),总生存期为39.7个月,显著长于化疗组16.8个月(P<0.05),5年生存率显著高于化疗组[85.92%(61/71)比45.71%(32/70)](P<0.05)。靶向组患者疾病控制率显著高于化疗组[46.48%(33/71)比12.86%(9/70)],总缓解率高于化疗组[14.89%(21/141)比0.71%(1/141)](P<0.05)。靶向组患者5年后临床治疗效果显著高于化疗组(P<0.05)。两组患者发生的不良反应均以Ⅰ~Ⅱ级和程度不等的Ⅲ级不良反应为主,未发生Ⅳ度不良反应,靶向组患者的不良反应发生率显著低于化疗组(P<0.05)。结论盐酸埃克替尼片靶向治疗晚期NSCLC患者具有较好的临床疗效,能够提高疾病控制率和总缓解率,延长5年生存率、无进展生存期和总生存期,不增加药物不良反应的发生率。
Objective To comparatively analyze the clinical efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitors-icotinib hydrochloride tablets and chemotherapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 177 patients with pathologically confirmed advanced NSCLC from May 2012 to May 2013 in Hebei Yanda Hospital were included in the study,and according to the treatment method,they were divided into a targeted group(88 cases)and a chemotherapy group(89 cases):the targeted group received icotinib hydrochloride tablets,and the chemotherapy group received pemetrexed plus cisplatin.The 5-year survival rate,progression free survival,overall survival,disease control rate,overall response rate and adverse reactions of the two groups were compared.Results The patients were followed up to 30 July 2018,36 cases(17 cases in the targeted group,19 cases in the chemotherapy group)were out of touch,forming the missing rate of 20.34%;in the targeted group,the progression free survival was 24.7 months,which was significantly higher than 15.4 months of the chemotherapy group(P<0.05).The overall survival was 39.7 months in the targeted group,which was significantly higher than 16.8 months of the chemotherapy group(P<0.05).The 5-year survival rate was 85.92%(61/71)in the targeted group,which was significantly higher than 45.71%(32/70)of the chemotherapy group(P<0.05).The disease control rate in the targeted group was significantly higher than that of the chemotherapy group[46.48%(33/71)vs 12.86%(9/70)](P<0.05),the overall response rate of the targeted group was significantly higher than that of the chemotherapy group[14.89%(21/141)vs 0.71%(1/141)](P<0.05).Five years later,the therapeutic effect of the targeted group was significantly higher than that of the chemotherapy group(P<0.05).The main adverse reactions of the two groups were mostly degreeⅠandⅡ,and some gradeⅢadverse reactions of varying degrees,no gradeⅣadverse reactions occurred in either group.
作者
王鸣
王晶
陈昕
刘春梅
王松
周静
刘龙
白秀会
孙梯业
WANG Ming;WANG Jing;CHEN Xin;LIU Chunmei;WANG Song;ZHOU Jing;LIU Long;BAI Xiuhui;SUN Tiye(Department of Oncology,Hebei Yanda Hospital,Sanhe 065201,China;Medical Records Statistics Office,Hebei Yanda Hospital,Sanhe 065201,China)
出处
《医学综述》
2019年第24期5016-5020,5025,共6页
Medical Recapitulate
关键词
晚期非小细胞肺癌
表皮生长因子受体酪氨酸激酶抑制剂
盐酸埃克替尼片
培美曲塞
化疗
Advanced non-small cell lung cancer
Epidermal growth factor receptor tyrosine kinase inhibitor
Icotinib hydrochloride tablets
Pemetrexed
Chemotherapy
